Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organovo Holdings (NQ: ONVO )

0.4000 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2
Open 0.4000
Bid (Size) 0.3801 (10)
Ask (Size) 0.4300 (15)
Prev. Close 0.4000
Today's Range 0.4000 - 0.4000
52wk Range 0.3154 - 1.740
Shares Outstanding 8,716,953
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
From Organovo, Inc.
Via GlobeNewswire
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
From Organovo, Inc.
Via GlobeNewswire

Performance

YTD
-64.29%
-64.29%
1 Month
-9.48%
-9.48%
3 Month
-36.00%
-36.00%
6 Month
-60.00%
-60.00%
1 Year
-66.10%
-66.10%

More News

Read More
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
Via Benzinga
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
From Organovo, Inc.
Via GlobeNewswire
ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024
Via InvestorPlace
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
From Organovo, Inc.
Via GlobeNewswire
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
From Organovo, Inc.
Via GlobeNewswire
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
From Organovo, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Organovo Stock Is Up Today
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
From Organovo, Inc.
Via GlobeNewswire
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
From Organovo, Inc.
Via GlobeNewswire
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
From Organovo, Inc.
Via GlobeNewswire
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
From Organovo, Inc.
Via GlobeNewswire
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
From Organovo, Inc.
Via GlobeNewswire
Organovo Highlights FXR314 Combination Therapy Potential and Plan
From Organovo, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.